Germany’s Merck KGaA (MRK: DE) today announced the presentation of detailed positive results from Part 1 of the global Phase ...

German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 earnings, citing foreign-exchange effects and uncertainty over tariffs.

Merck Animal Health, a unit of Merck , said on Thursday it would invest $895 million to expand its manufacturing facility in ...

The State of Kansas announced an $895 million capital expansion project at the Merck Animal Health manufacturing facility in ...

Merck (NYSE:MRK) operates within the healthcare sector, which plays a significant role in S&P 500 Index Fund index.

Merck is constructing a $1 billion drug manufacturing facility in Wilmington, Delaware, as part of its commitment to investment and growth in the United States. The company on Tuesday said it ...

Officially called Merck Wilmington Biotech ... which earlier this year received a $30.2-million grant from Delaware’s Council of Development Finance. The company’s presentation to the agency ...

Incyte's stock valuation is on the higher side given looming patent expiries for Jakafi and Opzelura, and uncertain pipeline ...

Merck KGaA (MRK: DE) plans to move its investigational lupus drug enpatoran into late-stage development, after new Phase II data showed clinically meaningful improvement in skin manifestations of the ...

KANSAS CITY, Mo. — The animal health division of global pharmaceutical company Merck is doubling down on its operations in De Soto. Merck Animal Health, along with local, regional and state ...

The $895 million capital expansion will be constructed on an existing Merck-owned property that is the site of its biologics facility in De Soto, Kansas. It includes an $860 million investment in ...

Merck, known as MSD outside of the United States and Canada, announced the start of construction for a $1 billion, 470,000-square-foot state-of-the-art biologics center of excellence in Wilmington, ...